about
MAO-inhibitors in Parkinson's DiseaseEmerging approaches in Parkinson's disease - adjunctive role of safinamideOxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventionsCardiovascular considerations in antidepressant therapy: an evidence-based reviewInfluence of Pharmacotherapy on Cognitive Functions in Depression: A Review of the LiteratureInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyRasagiline: a review of its use in the management of Parkinson's diseaseOpportunities to minimise risk in drug discovery and development.Antidepressant effect of geranylgeranylacetone in a chronic mild stress model of depression and its possible mechanismCalcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology.MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells.Monoamine oxidases as sources of oxidants in the heartEvaluation of plant phenolic metabolites as a source of Alzheimer's drug leads.Targeting imidazoline site on monoamine oxidase B through molecular docking simulations.The antidepressant trans-2-phenylcyclopropylamine protects mice from high-fat-diet-induced obesity.8-Benzyltetrahydropyrazino[2,1-f]purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases.Cellular and molecular mechanisms in the long-term action of antidepressantsClinical use of antidepressant therapy and associated cardiovascular riskNeuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?Rasagiline in the pharmacotherapy of Parkinson's disease--a review.Tranylcypromine: new perspectives on an "old" drug.Pharmacological management of panic disorder.Pharmacotherapy of panic disorder.Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Tranylcypromine reduces herpes simplex virus 1 infection in mice.In vitro safety pharmacology profiling: what else beyond hERG?Drug therapy in patients with Parkinson's disease.Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.Current status of safinamide for the drug portfolio of Parkinson's disease therapy.Safinamide for the treatment of Parkinson's disease.Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection.Binge ethanol exposure increases the Krüppel-like factor 11-monoamine oxidase (MAO) pathway in rats: Examining the use of MAO inhibitors to prevent ethanol-induced brain injuryUse of monoamine oxidase inhibitors in chronic neurodegeneration.Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.Rasagiline in treatment of Parkinson's disease.
P2860
Q24629770-0DED02A7-2441-4863-9AF9-B57A55F6B8C8Q26740905-4F1F2185-2CA6-44B0-8084-033CCD6638BBQ26851676-7A28A167-25DE-4B1E-A548-4E9027ECD110Q27021843-2C3C3F88-DC8A-4D18-9CFF-8C914475C25DQ27694555-95A6A21E-78D1-4C30-8396-2DF4C747306DQ28069609-4CC091E6-8E39-4FDD-900D-825838554367Q28239730-DE827A8E-8A6E-4592-A4F6-81D905F7BD96Q30428283-BC6F515F-5E84-4819-B72F-AF6CA7143081Q30448619-D14208B3-F6F2-4E49-8D71-9F688CB5B2D6Q33299033-8F1B06E0-632C-4F52-B101-7CE3AADA377EQ33556950-4DD2AFCA-C0C3-42D5-8C69-3074C337CD50Q33723676-2677802E-0D8C-4A1F-876E-E0F9EE996D9AQ33791575-BC7DA1F4-FA64-45A9-A54D-A691ACB32229Q34199067-A12D813A-EB00-445F-A31B-259A55C26766Q35106846-651DF938-5D9B-4865-8FF6-BB24FF2BC1ACQ35166780-3F5F9F6A-9192-4CD8-8632-79D7ED4279C2Q35237067-EBFE2FB1-5B96-43C0-982B-7946963E00F4Q36184863-9B9CE7EA-AA30-4943-A11E-79797BFAE948Q36188726-7409B509-9C9B-4ABF-872F-050025552A24Q36273444-20F8E6E1-F38F-415E-A57C-6DB71646235CQ36574603-7DF3915A-C719-4CD4-AE56-27FFF17CF387Q36836798-232864D3-84DD-4A14-B366-BE8CE3DAD6FEQ36876452-DA62EA6A-8AB1-4A16-88D3-BB43E32578D4Q37401135-31C96227-ABF0-451D-94A9-C53A0304CC8AQ37578490-A7C91C9F-6B46-4F56-9484-365936B50E6FQ37712992-A7253078-0E73-40FF-AC05-C4E17B285FF1Q37855844-8EBE1935-B1E1-4197-87EB-89AE2D2D9B6CQ38064971-BACFF757-B2F0-4DDD-82A7-5649A722F3CEQ38103966-9988C370-D42C-4091-9294-D62449F2B0DBQ38112217-3FB4345A-F303-4A85-876C-62F4791F1A30Q38140018-28B05509-FEA7-4EF6-BAC2-C2CC53653E53Q38197710-37EEAE85-1840-4DA1-9565-2EBD1803CB00Q38325601-FA04595A-203A-456B-9E96-4371083FC60DQ38636630-414750A3-9C83-46EE-8E36-BFFA5BC94A92Q38817972-370E6143-9719-493C-ABB8-08F3D5BD0586Q38888524-26B2719E-22EC-423D-A041-214ECED21F3DQ38916785-ECAFBB34-7BD1-4E70-A58A-BD69409F013BQ39044780-45CCABAC-DCAE-4584-AF62-9F5C4387B1DDQ39280910-6A5865D1-B471-4711-97FE-A37DC90B7ACEQ39315311-6339FEDB-01FE-4007-AD8A-11189A8AD953
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Clinical applications of MAO-inhibitors.
@ast
Clinical applications of MAO-inhibitors.
@en
Clinical applications of MAO-inhibitors.
@nl
type
label
Clinical applications of MAO-inhibitors.
@ast
Clinical applications of MAO-inhibitors.
@en
Clinical applications of MAO-inhibitors.
@nl
prefLabel
Clinical applications of MAO-inhibitors.
@ast
Clinical applications of MAO-inhibitors.
@en
Clinical applications of MAO-inhibitors.
@nl
P2093
P356
P1476
Clinical applications of MAO-inhibitors.
@en
P2093
P304
P356
10.2174/0929867043364775
P577
2004-08-01T00:00:00Z